Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Galmed Adds China Arm to Global Trial of NASH/Fibrosis Treatment

publication date: May 3, 2021

Galmed Pharma, an Israeli biopharma, was approved to add a China arm to its global Phase III trial of Aramchol in patients with NASH and fibrosis. Aramchol is a novel fatty acid bile acid conjugate that targets SCD1 to modulate hepatic lipid metabolism. In animal models, it down regulated steatosis, inflammation and fibrosis, all NASH-associated pathologies. Galmed develops novel products to treat liver, metabolic and inflammatory diseases. More details....

Stock Symbol: (NSDQ: GLMD)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021